Copyright
©2009 Baishideng.
World J Hepatol. Oct 31, 2009; 1(1): 8-16
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.8
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.8
Table 4 Randomized control trial (TACE)
| Author | Country and region | Publication year | Treatment schedule | Root | n | RR (%) | 1yrs (%) | 2yrs (%) | 3yrs (%) |
| Group d'Etude | France | 1995 | CDDP/Lip (70 mg/10 mL) + GS | Lip-TACE | 50 | 16.3 | 62.0 | 37.8 | - |
| et de Traitment | |||||||||
| du Carcinome | |||||||||
| Hepatocellulaire[51] | Conservative management | - | 46 | 5.0 | 43.5 | 26.0 | - | ||
| Lo et al[39] | Hong Kong | 2002 | CDDP/saline + Lip (1:1), | Lip-TACE | 40 | 39.0 | 57.0 | 31.0 | 26.0 |
| (median: 10 mg/20 mL/body | |||||||||
| max: 30 mg/60 mL/body) + GS | |||||||||
| conservative management | - | 39 | 6.0 | 32.0 | 11.0 | 3.0 |
- Citation: Ishikawa T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol 2009; 1(1): 8-16
- URL: https://www.wjgnet.com/1948-5182/full/v1/i1/8.htm
- DOI: https://dx.doi.org/10.4254/wjh.v1.i1.8